Search Results - "Meier, Urs R"

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial by Pless, Miklos, Dr, Stupp, Roger, Prof, Ris, Hans-Beat, Prof, Stahel, Rolf A, Prof, Weder, Walter, Prof, Thierstein, Sandra, Gerard, Marie-Aline, PhD, Xyrafas, Alexandros, Früh, Martin, MD, Cathomas, Richard, MD, Zippelius, Alfred, MD, Roth, Arnaud, MD, Bijelovic, Milorad, MD, Ochsenbein, Adrian, Prof, Meier, Urs R, MD, Mamot, Christoph, MD, Rauch, Daniel, MD, Gautschi, Oliver, MD, Betticher, Daniel C, MD, Mirimanoff, René-Olivier, Prof, Peters, Solange, MD

“…Summary Background One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung cancer is neoadjuvant chemotherapy and surgery. We did a…”
Get full text

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis by Helfenstein, Seth, Riesterer, Oliver, Meier, Urs R, Papachristofilou, Alexandros, Kasenda, Benjamin, Pless, Miklos, Rothschild, Sacha I

“…Concurrent chemoradiotherapy with cisplatin is standard for patients (pts) with loco-regionally advanced squamous cell carcinoma of the head and neck…”
Get full text

Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy by Panje, Cédric M, Höng, Laura, Hayoz, Stefanie, Baracos, Vickie E, Herrmann, Evelyn, Garcia Schüler, Helena, Meier, Urs R, Henke, Guido, Schacher, Sabina, Hawle, Hanne, Gérard, Marie-Aline, Ruhstaller, Thomas, Plasswilm, Ludwig

“…Sarcopenia, the critical depletion of skeletal muscle mass, is an independent prognostic factor in several tumor entities for treatment-related toxicity and…”
Get full text

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC by König, David, Meier, Urs R., Klaeser, Bernd, Savic, Spasenija, Pless, Miklos

“…Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are established effective therapies in patients with ALK-rearranged advanced non-small-cell…”
Get full text

Severe reaction to radiotherapy provoked by hypomorphic germline mutations in ATM (ataxia–telangiectasia mutated gene) by Asadollahi, Reza, Britschgi, Christian, Joset, Pascal, Oneda, Beatrice, Schindler, Detlev, Meier, Urs R., Rauch, Anita

“…Background A minority of breast cancer (BC) patients suffer from severe reaction to adjuvant radiotherapy (RT). Although deficient DNA double‐strand break…”
Get full text

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08) by von Moos, Roger, Koeberle, Dieter, Schacher, Sabina, Hayoz, Stefanie, Winterhalder, Ralph C., Roth, Arnaud, Bodoky, György, Samaras, Panagiotis, Berger, Martin D., Rauch, Daniel, Saletti, Piercarlo, Plasswilm, Ludwig, Zwahlen, Daniel, Meier, Urs R., Yan, Pu, Izzo, Paola, Klingbiel, Dirk, Bärtschi, Daniela, Zaugg, Kathrin

“…KRAS mutation occurs in ∼40% of locally advanced rectal cancers (LARCs). The multitarget tyrosine kinase inhibitor sorafenib has radiosensitising effects and…”
Get full text

Avoiding glucocorticoid administration in a neurooncological case by Rutz, Hans Peter, Hofer, Silvia, Peghini, Pietro E, Gutteck-Amsler, Ursula, Rentsch, Katharina, Meier-Abt, Peter J, Meier, Urs R, Bernays, René Ludwig

“…Restricting glucocorticoid (GC) use in the treatment of patients with a solid tumor may help improving outcome. Here, we report administration of celecoxib…”
Get full text

Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08 by Von Moos, Roger, Koeberle, Dieter, Schacher, Sabina, Hayoz, Stefanie, Winterhalder, Ralph C., Roth, Arnaud, Bodoky, Gyorgy, Samaras, Panagiotis, Berger, Martin D, Rauch, Daniel, Saletti, Piercarlo, Plasswilm, Ludwig, Thum, Peter, Meier, Urs R., Yan, Pu, Izzo, Paola, Klingbiel, Dirk, Baertschi, Daniela, Zaugg, Kathrin

“…Abstract only…”
Get full text

Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00) by Pless, Miklos, Stupp, Roger, Ris, Hans-Beat, Stahel, Rolf A., Weder, Walter, Thierstein, Sandra, Xyrafas, Alexandros, Frueh, Martin, Cathomas, Richard, Zippelius, Alfred, Roth, Arnaud, Bijelovic, Milorad, Ochsenbein, Adrian, Meier, Urs R., Mamot, Christoph, Rauch, Daniel, Gautschi, Oliver, Betticher, Daniel C., Mirimanoff, Rene-Olivier, Peters, Solange

“…Abstract only 7503 Background: For stage III/N2 NSCLC neoadjuvant chemotherapy (NCT) followed by radical surgery is one standard treatment approach. In our…”
Get full text

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC by König, David, Meier, Urs R, Klaeser, Bernd, Savic, Spasenija, Pless, Miklos

Get full text

Avoiding glucocorticoid administration in a neurooncological case by Rutz, Hans Peter, Hofer, Silvia, Peghini, Pietro E., Gutteck-Amsler, Ursula, Rentsch, Katharina, Meier-Abt, Peter J., Meier, Urs R., Bernays, René Ludwig

“…Restricting glucocorticoid (GC) use in the treatment of patients with a solid tumor may help improving outcome. Here, we report administration of celecoxib…”
Get full text